Phelan Nancy R.
Transaction: 07/27/2026
BUY
Change
+16,700
Price
Not reported
Filing
07/29/2026
Type
BUY
Achieve Life Sciences, Inc.
ACHV • Biotechnology
$6.51
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$608.75M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.69Healthy liquidity · 4.39Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:11 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$6.51
Change0.00%
Shares Out93.51M
Market Cap$608.75M
Enterprise Value$436.40M
52W Range2.46 - 7.11
Beta2.23
P/E-5.34
P/B-41.48
P/FCF-12.94
EV/EBITDA-11.20
EV/FCF-9.28
Price$6.51
Change0.00%
Shares Out93.51M
Market Cap$608.75M
Enterprise Value$436.40M
52W Range2.46 - 7.11
Beta2.23
P/E-5.34
P/B-41.48
P/FCF-12.94
EV/EBITDA-11.20
EV/FCF-9.28
Earnings Yield-18.73%
FCF Yield-7.73%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.69
Current Ratio4.39
Quick Ratio4.39
Revenue 5Y-100.00%
Target$15.25
Target Upside134.25%
Target Median$15.50
Target Range12.00 - 18.00
Volume1.41M
Avg Volume1.72M
EPS Surprise0.11
Investment DNA
How strong this company looks for long-term investors
34
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
72/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Manageable debt level · 0.69Healthy liquidity · 4.39Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 6 analyst votes · 2026-10-20
100/100
Bullish
Bullish
6
Hold
0
Bearish
0
Price Target
2026-08-13
Low
$12.00
Mean
$14.00
Median
$13.00
High
$18.00
Insider Transactions
Recent executive and insider activity
Phelan Nancy R.
Transaction: 07/27/2026
BUY
Change
+25,000
Price
$6.18
Filing
07/29/2026
Type
BUY
Farrow Jeffrey S
Transaction: 07/27/2026
BUY
Change
+16,700
Price
Not reported
Filing
07/29/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Phelan Nancy R. | BUY | +16,700 | Not reported | 07/27/2026 | 07/29/2026 |
| Phelan Nancy R. | BUY | +25,000 | $6.18 | 07/27/2026 | 07/29/2026 |
| Farrow Jeffrey S | BUY | +16,700 | Not reported | 07/27/2026 | 07/29/2026 |
| Farrow Jeffrey S | BUY | +25,000 | $6.18 | 07/27/2026 | 07/29/2026 |
| Stewart Richard Alistair | BUY | +16,700 | Not reported | 07/27/2026 | 07/29/2026 |
| Stewart Richard Alistair | BUY | +25,000 | $6.18 | 07/27/2026 | 07/29/2026 |
| Waldman Reid Alexander | BUY | +16,700 | Not reported | 07/27/2026 | 07/29/2026 |
| Waldman Reid Alexander | BUY | +25,000 | $6.18 | 07/27/2026 | 07/29/2026 |
| Royston Aaron | BUY | +16,700 | Not reported | 07/27/2026 | 07/29/2026 |
| Royston Aaron | BUY | +25,000 | $6.18 | 07/27/2026 | 07/29/2026 |
| Martin Christopher Nathan | BUY | +16,700 | Not reported | 07/27/2026 | 07/29/2026 |
| Martin Christopher Nathan | BUY | +25,000 | $6.18 | 07/27/2026 | 07/29/2026 |
| Sellig Thomas | BUY | +16,700 | Not reported | 07/27/2026 | 07/29/2026 |
| Sellig Thomas | BUY | +25,000 | $6.18 | 07/27/2026 | 07/29/2026 |
| Farrow Jeffrey S | OTHER | 0 | Not reported | 05/29/2026 | 06/02/2026 |
| Waldman Reid Alexander | OTHER | 0 | Not reported | 05/29/2026 | 06/02/2026 |
| Farrow Jeffrey S | BUY | +47,250 | $5.24 | 05/29/2026 | 06/02/2026 |
| Waldman Reid Alexander | BUY | +47,250 | $5.24 | 05/29/2026 | 06/02/2026 |
| Martin Christopher Nathan | OTHER | 0 | Not reported | 05/11/2026 | 05/13/2026 |
| Martin Christopher Nathan | BUY | +47,250 | $5.59 | 05/11/2026 | 05/13/2026 |